– UK, Oxford – SpyBiotech, a biotechnology company pioneering novel vaccine platform technologies, announced the appointment of Dr. Stuart Chaffee (PhD) to its Board as an Independent Director.
About Dr. Stuart Chaffee
Dr. Stuart Chaffee is CEO of QuantX Biosciences and brings over two decades of experience in the biotechnology and biopharma industry. He has played a pivotal role in the inception of four publicly traded biotechnology companies and has successfully raised over $900 million in private and public capital.
In his previous operating role as CBO at Affinivax, Inc., Dr. Stuart Chaffee was instrumental in driving the company’s strategic growth, culminating in its acquisition by GSK for up to $3.3 billion. His expertise in business development and advising innovative biotech ventures positions him to provide invaluable strategic guidance as SpyBiotech advances its clinical pipeline and expands its proprietary SpyTag/SpyCatcher™ and other related protein superglue technology.
About SpyBiotech
SpyBiotech is a clinical-stage biotechnology company with novel vaccine platform technologies that can target infectious diseases, cancer, and chronic diseases. The company was spun out of the University of Oxford in 2017, backed by Oxford Science Enterprises (OSE) and Google Ventures (GV). Based on science developed at the University of Oxford, SpyBiotech’s novel vaccine platform is based on a proprietary protein “superglue” technology, which binds antigens to vaccine delivery platforms in a way that minimizes delivery risk and enhances immunogenicity and efficacy. This makes it ideal for use against infectious diseases in challenging environments, such as in the developing world, but also with potential application in non-infectious disease settings such as cancer. SpyBiotech has the exclusive rights from the University of Oxford to apply, commercialize, and sublicense the SpyTag/SpyCatcher and related technology in vaccine development.
SpyBiotech’s platform leverages the SpyTag/SpyCatcher system—a protein superglue that enables rapid, efficient, and stable antigen binding to vaccine delivery platforms. This technology offers a plug-and-play approach to vaccine development, minimizing risks while enhancing immunogenicity. The company recently completed vaccinations in its Phase I trial for SPYVLP01, a vaccine candidate targeting cytomegalovirus (CMV), underscoring the critical momentum towards addressing a pathogen that leads to chronic developmental health consequences.
For more: https://spybiotech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.